Hi Cody, I told Luke your post and agree with
Post# of 36537
I told Luke your post and agree with most of it, however, in regards to the longer term prospects die value to be added to the enterprise, I would add Oral-lyn, as diabetes is a more than linearly growing problem especially in the western "civilized" world. With vastly increasing numbers of diabetics, I am sure that Oral-lyn will be a highly profitable product for GNBT.
Beyond the immediate vaccine development opportunity lie the remainder of the new company’s potential including cancer vaccines. that’s where the real long term value is to be found.